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Background: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive
metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and
efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting.
Patients and methods: In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive
advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine
therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8mg/kg loading dose, then 6mg/kg every 3weeks
(q3w)] and pertuzumab (840mg loading dose, then 420mg q3w) until disease progression or unacceptable toxicity. The primary
end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS).
Results: Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nab-
paclitaxel in 65; 7 discontinued before starting taxane). Median age was 54 years; 29% had received prior trastuzumab. Median
treatment duration was 16months for pertuzumab and trastuzumab and 4months for taxane. Compared with docetaxel-containing
therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but
less febrile neutropenia (1% versus 11%) andmucositis (14% versus 25%). At this preliminary analysis (52 months’ median follow-up),
median PFS was 20.6 [95% confidence interval (CI) 18.9–22.7] months overall (19.6, 23.0 and 18.1months with docetaxel, paclitaxel
and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%–82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%).
Conclusions: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and
taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane
backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile.
ClinicalTrials.gov: NCT01572038.
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Introduction
For patients with HER2-positive breast cancer, HER2-directed
therapy is established as the standard of care. In the first-line
metastatic setting, dual HER2 blockade demonstrated improved
outcomes compared with a single HER2-directed therapy:
progression-free survival (PFS) and overall survival (OS) were
significantly improved with the addition of pertuzumab to tras-
tuzumab plus docetaxel in the randomised phase III
CLEOPATRA trial [1, 2]. These results led to regulatory approval
of the regimen in Europe and the United States and its rapid
adoption into treatment guidelines by the American Society of
Clinical Oncology, the National Comprehensive Cancer Network
and the Advanced Breast Cancer 4 guidelines [3–5].
In many countries, paclitaxel is considered the first-line taxane
of choice for patients with metastatic breast cancer, and is pre-
ferred to docetaxel because of its more tolerable acute toxicity
profile [6]. Particularly in older patients, the approved dose of
docetaxel 100 mg/m2 may not be considered appropriate [7].
There is no evidence that paclitaxel agents (solvent based or
nanoparticle bound) are less effective than docetaxel; on the con-
trary, nab-paclitaxel demonstrated improved PFS compared with
docetaxel in a prospective randomised trial [8]. Nanoparticle
albumin-bound (nab)-paclitaxel appears to offer similar efficacy
to docetaxel, with less frequent neutropenia but more frequent
sensory neuropathy [9, 10]. A single-arm study (N¼ 51) evaluat-
ing weekly paclitaxel combined with trastuzumab and pertuzu-
mab as first- or second-line therapy reported median PFS of
25.7 months and median OS of 33 months [11]. However, con-
clusions are limited by the small sample size.
The PERtUzumab global SafEty (PERUSE) study was initiated
to assess the safety and efficacy of three widely used taxanes in
combination with dual HER2 targeting in the first-line locally re-
current/metastatic breast cancer (LR/MBC) setting. Here we re-
port preliminary safety and efficacy analyses representing a
snapshot of current data from this ongoing study, with a particu-
lar focus on subgroup analyses according to the taxane backbone
combined with pertuzumab and trastuzumab. Data entry and
cleaning will continue until database lock for the final analysis
(prespecified 60 months after last patient enrolment), which is
expected in 2020.
Patients and methods
PERUSE (NCT01572038) is a global open-label single-arm phase IIIb
study evaluating the safety and tolerability of pertuzumab in combin-
ation with trastuzumab and a taxane. Eligible patients were male or fe-
male, aged 18 years, with HER2-positive LR/MBC not amenable to
curative resection. HER2 positivity was defined as 3þ staining by immu-
nohistochemistry or positive by in situ hybridisation according to local
assessment of the primary tumour and/or metastatic site. All patients had
to have at least one measurable lesion and/or non-measurable disease
evaluable according to Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1. Patients with central nervous system metastases
were eligible if they were stable for 3 months preceding screening after
receiving local therapy without anti-HER2 therapy. Patients were
required to have Eastern Cooperative Oncology Group performance sta-
tus 2, life expectancy 12 weeks, left ventricular ejection fraction
(LVEF)50% and to have received no prior systemic therapy (except2
lines of endocrine therapy, one of which may have been in combination
with everolimus) for LR/MBC. Any prior anti-HER2 agent (approved or
investigational) other than (neo)adjuvant trastuzumab and/or lapatinib
was prohibited. Patients with disease progression during (neo)adjuvant
trastuzumab and/or lapatinib therapy were excluded, as were patients
with recurrence within 6 months of completing (neo)adjuvant non-
hormonal systemic therapy. Additional exclusion criteria included his-
tory of persistent grade 2 haematological toxicity related to previous
(neo)adjuvant therapy, ongoing grade 3 peripheral neuropathy or
inadequate organ function.
Investigators selected their preferred taxane agent (docetaxel, pacli-
taxel or nab-paclitaxel), administered weekly or every 3 weeks (q3w)
according to local prescribing information and/or recognised guidelines.
Taxane therapy was given in combination with pertuzumab (Perjeta
VR
,
F. Hoffmann-La Roche Ltd, Basel, Switzerland) 840 mg as a loading dose,
reduced to 420 mg for subsequent cycles administered q3w, and trastuzu-
mab (Herceptin
VR
, F. Hoffmann-La Roche Ltd) 8 mg/kg as a loading dose,
reduced to 6 mg/kg for subsequent cycles administered q3w. The proto-
col allowed switching to an alternative taxane during treatment. Study
medication was administered until unacceptable toxicity, disease pro-
gression, withdrawal of consent or death, whichever occurred first.
LVEF was assessed by either echocardiography (preferred) or multi-
gated acquisition scan within 42 days of enrolment and every three
treatment cycles (7 days before study drug administration) thereafter.
In the event of an LVEF measurement 45%, a strict algorithm for
treatment interruption, continuation or permanent discontinuation was
implemented (supplementary Figure S1, available at Annals of Oncology
online). Adverse events (AEs) were coded according to the Medical
Dictionary for Regulatory Activities (version 21.0) and severity was
graded according to National Cancer Institute Common Terminology
Criteria for Adverse Events (version 4.0). Patients participating in the
PERUSE study will be followed up until at least 60 months after enrol-
ment of the last patient or until all patients in the study have withdrawn
consent or died, whichever occurs first.
The primary objective of PERUSE is to evaluate the safety and toler-
ability of pertuzumab in combination with trastuzumab and a taxane.
Safety outcome measures include the incidence and severity of AEs and
LVEF measurements. Secondary outcome measures include PFS, OS,
overall response rate (ORR), clinical benefit rate, duration of response,
time to response and patient-reported outcomes.
Investigators assessed tumour response using computed tomography
or magnetic resonance imaging scans (and isotope bone scan if indicated)
according to RECIST (version 1.1). Objective responses were confirmed
4 weeks after initial documentation. Tumour assessments were carried
out every three cycles for the first 3 years, and every six cycles thereafter in
patients who remained progression free.
Safety analyses were based on the safety population, comprising all
enrolled patients who received at least one dose of study treatment. In the
present analysis, patients were allocated to each taxane subgroup accord-
ing to the first taxane they received during study therapy. PFS was esti-
mated using the Kaplan–Meier method in the intent-to-treat (ITT)
population, defined as all enrolled patients. ORR analysis was based on
the best (confirmed) overall response as assessed by investigators in all
enrolled patients with measurable disease at baseline. The number and
proportion of responders and non-responders in patients with measur-
able disease were reported for each treatment group, together with two-
sided 95% confidence intervals (CIs). Patients without a post-baseline tu-
mour assessment were considered to be non-responders. Subgroup anal-
yses according to the type of taxane were prespecified in the protocol.
All analyses are descriptive. No formal statistical hypothesis tests were
carried out. There were no adjustments for multiplicity of end points or
comparisons within subgroups.
The study was carried out in accordance with the Good Clinical
Practice guidelines and the Declaration of Helsinki, and all patients pro-
vided written informed consent. The protocol and all accompanying
materials provided to patients were approved by independent ethics
committees at the participating institutions. An independent data moni-
toring committee reviewed study data at prespecified intervals during en-
rolment and then annually after completion of enrolment.
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Results
Patient population
Between 11 May 2012 and 16 September 2014, 1667 patients were
screened, of whom 1436 were enrolled from sites in Europe
(N¼ 1009), Asia (N¼ 177), South America (N¼ 121), Africa
(N¼ 71), Canada (N¼ 34) and Australia (N¼ 24). A total of
1436 patients received pertuzumab, 1435 received trastuzumab
and 1429 received a taxane. One patient discontinued therapy
immediately after the first pertuzumab administration and there-
fore received neither trastuzumab nor taxane; six additional
patients discontinued all study treatments before receiving their
first taxane dose. The initial taxane selected by the investigator
was docetaxel in 775 patients (54%), paclitaxel in 589 patients
(41%) and nab-paclitaxel in 65 patients (5%). Although
information on paclitaxel treatment schedule was not collected,
approximately two-thirds of patients received two or more
doses per cycle, suggesting that a weekly paclitaxel regimen was
administered. There were some notable differences between
countries in chemotherapy selection: docetaxel was selected for
all patients in Africa, Poland, Finland and Estonia, whereas in
Germany, Israel, Ukraine, Belgium, Canada, The Netherlands,
Peru, Argentina, Hong Kong and Ecuador, 60% of patients
received paclitaxel chemotherapy. More than half of all patients
receiving nab-paclitaxel were treated in Germany or Australia.
A total of 52 patients (4%) switched taxane at least once during
the study (25 from docetaxel to paclitaxel, 16 from paclitaxel
to docetaxel).
Baseline characteristics and prior therapy are summarised
in Table 1 and supplementary Table S1, available at Annals of
Oncology online. The main differences between the chemotherapy
subgroups were the slightly older age and worse performance
status in the paclitaxel subgroup, and the higher proportion
of patients with de novo metastatic disease in the docetaxel
subgroup.
Treatment exposure
At the data cut-off for this preliminary analysis (16 March 2018),
the median duration of follow-up was 52.2 months (95% CI
51.5–52.7). The median duration of anti-HER2 therapy was 24
cycles (range 1–99) (16 months) for both pertuzumab and trastu-
zumab. The median duration of taxane exposure was six cycles
(range 1–70), corresponding to 4.0 months (3.8, 4.2 and
3.9 months for docetaxel, paclitaxel and nab-paclitaxel, respect-
ively) (supplementary Table S2, available at Annals of Oncology
online). Treatment was ongoing in 270 patients, of whom 75 had
discontinued at least one of the component drugs, predominantly
taxane (73 patients). Of the 1166 patients who had discontinued
all study treatment, 348 remained in follow-up. Disease progres-
sion was the most common reason for discontinuing pertuzumab
(57%) and trastuzumab (56%), with only 9% of patients discon-
tinuing either anti-HER2 agent because of AEs (supplementary
Table S3, available at Annals of Oncology online). In contrast, rea-
sons for discontinuing taxane therapy were more varied (AEs in
18%, investigator decision or disease progression each in 17%,
and ‘other’ reason in 30%).
Safety
In the overall population, the most common AEs (any grade)
were diarrhoea (68%), alopecia (48%), nausea (35%) and fatigue
(32%). Although these AEs were among the most common with
all three chemotherapy backbones, some differences in safety
profile were apparent between the subgroups. Neuropathy and
epistaxis were more common with paclitaxel and nab-paclitaxel
than with docetaxel, whereas febrile neutropenia and mucosal in-
flammation were more common with docetaxel than with either
paclitaxel formulation (supplementary Table S4, available at
Annals of Oncology online).
The most common grade 3 AEs were neutropenia (10%),
diarrhoea (8%) and febrile neutropenia (6%). The incidences of
grade 3 neutropenia and febrile neutropenia were highest with
docetaxel and lowest with nab-paclitaxel (Figure 1). The inciden-
ces of grade3 diarrhoea and other grade3 AEs were generally
similar in the three taxane subgroups. Fatal AEs were reported in
16 patients (2%) in the docetaxel subgroup [infections in 0.6%,
cardiac disorders in 0.5%, hepatic failure in 0.3% and neutro-
penia, acute respiratory distress syndrome, hypoglycaemia, spon-
taneous abortion (although not fatal for the patient), delirium
and unexplained death each in 0.1%], 19 patients (3%) in the
paclitaxel subgroup (infections and unexplained death each in
0.8%, cardiac disorders in 0.5%, pancreatitis and haematological
AEs each in 0.3% and hepatic encephalopathy, ischaemic stroke
and bronchial aspiration each in 0.2%) and one patient (2%) in
the nab-paclitaxel subgroup (pneumonitis).
The AEs most commonly leading to treatment discontinuation
for both pertuzumab and trastuzumab were ejection fraction
decreased (2.3%), cardiac failure (0.8%) and left ventricular dys-
function (0.6%). For taxane discontinuation, the most common
AEs were peripheral neuropathy (3.7%), paraesthesia, peripheral
sensory neuropathy (both 1.7%), fatigue (1.2%) and diarrhoea
(1.1%).
In the overall safety population across all timepoints, LVEF
remained above 50% in most patients (86%). In 24 patients
(2%), the worst recorded LVEF was 45%–50% with a decrease
from baseline of <10% points; in 69 patients (5%), the worst
recorded LVEF was 45%–50% with a decrease from baseline of
10% points. Sixty patients (4%) had an LVEF <45%. LVEF
measurements were missing in 46 patients (3%), 35 of whom dis-
continued from the study before the scheduled date of their first
post-baseline LVEF assessment. There was no recognisable pat-
tern for the timing of LVEF decrease.
Efficacy
Best overall response was evaluable in 1199 patients with meas-
urable disease at baseline. The ORR was 80% (95% CI 78%
to 82%), including confirmed complete responses in 15%. An
additional 15% of patients had stable disease as their best over-
all response. ORRs were similar in the three taxane subgroups
(Table 2).
At the data cut-off date, PFS events had been recorded in
986 patients (69%). Median PFS was 20.6 months (95% CI 18.9–
22.7) in the ITT population (Figure 2A). Median PFS according
to the initial taxane was 19.6 months (95% CI 16.9–21.8) with
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docetaxel, 23.0 months (95% CI 19.8–25.8) with paclitaxel and
18.1 months (95% CI 12.2–32.3) with nab-paclitaxel (Figure 2B).
Further subgroup analyses according to hormone receptor sta-
tus are shown in Figure 2C and D. In the hormone receptor-
positive subgroup, median PFS was 19.8 months (95% CI
16.6–23.3) with docetaxel, 22.7 months (95% CI 19.2–25.8) with
paclitaxel and 15.4 months (95% CI 10.2–31.6) with nab-
paclitaxel. In the hormone receptor-negative subgroup, median










Median (range) 54 (23–87) 53 (23–82) 56 (26–87) 53 (31–81)
65 312 (22) 137 (18) 158 (27) 14 (22)
75 81 (6) 29 (4) 46 (8) 4 (6)
ECOG PSa
0 851 (59) 487 (63) 320 (54) 43 (66)
1 521 (36) 267 (34) 229 (39) 21 (32)
2 63 (4) 20 (3) 40 (7) 1 (2)
Sex
Female 1429 (100) 772 (100) 587 (100) 63 (97)
Male 7 (<1) 3 (<1) 2 (<1) 2 (3)
Stage at initial diagnosis
I 116 (8) 54 (7) 56 (10) 5 (8)
II 395 (28) 193 (25) 184 (31) 18 (28)
III 400 (28) 219 (28) 148 (25) 29 (45)
IV 509 (35) 298 (38) 196 (33) 13 (20)
Not done 16 (1) 11 (1) 5 (1) 0
Median time since initial breast cancer diagnosis, months (range) 26.5 (0.2–383.0b) 19.2 (0.2–383.0) 28.1 (0.3–366.2) 33.5 (0.3–283.8)
Hormone receptor statusb
ER and/or PgR positive 918 (64) 491 (63) 377 (64) 46 (71)
ER and PgR negative 512 (36) 279 (36) 211 (36) 19 (29)
Metastatic sites
Visceral 1000 (70) 552 (71) 401 (68) 42 (65)
Prior chemotherapy 680 (47) 348 (45) 293 (50) 36 (55)
Neoadjuvant 219 (15) 115 (15) 92 (16) 12 (18)
Adjuvant 516 (36) 265 (34) 222 (38) 26 (40)
Metastatic/advanced 2 (<1) 1 (<1) 1 (<1) 0
Otherc 1 (<1) 0 1 (<1) 0
Type of chemotherapy
Anthracycline 570 (40) 301 (39) 241 (41) 26 (40)
Taxane 380 (26) 187 (24) 170 (29) 21 (32)
Endocrine therapy 409 (28) 201 (26) 181 (31) 24 (37)
Neoadjuvant 8 (1) 5 (1) 3 (1) 0
Adjuvant 348 (24) 173 (22) 154 (26) 18 (28)
Metastatic/advanced 92 (6) 43 (6) 42 (7) 7 (11)
Other 4 (<1) 1 (<1) 3 (1) 0
Trastuzumab 416 (29) 212 (27) 176 (30) 26 (40)
Neoadjuvant 81 (6) 43 (6) 33 (6) 5 (8)
Adjuvant 381 (27) 195 (25) 159 (27) 25 (38)
Metastatic/advanced 3 (<1) 0 2 (<1) 1 (2)
Other 6 (<1) 1 (<1) 5 (1) 0
Radiotherapy 661 (46) 332 (43) 289 (49) 36 (55)
Surgery 1109 (77) 579 (75) 472 (80) 53 (82)
aMissing in one patient in the docetaxel subgroup.
bUnknown in six patients (five in the docetaxel subgroup and one in the paclitaxel subgroup; two patients with unknown ER and PgR, four patients
negative for one receptor and unknown for the other).
cLocally advanced.
All data are N (%) unless otherwise indicated.
ECOG PS, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; PgR, progesterone receptor.
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PFS was 17.8 months (95% CI 15.0–22.8) with docetaxel,
24.2 months (95% CI 17.9–29.7) with paclitaxel and 32.3 months
(95% CI 9.1–not evaluable) with nab-paclitaxel.
OS results were not mature at this data cut-off. Among the 545
patients (38%) who had died at the time of data cut-off, the ma-
jority (462; 85%) had died from disease progression.
Discussion
The PERUSE study population of 1436 patients treated with tras-
tuzumab, pertuzumab and taxane therapy represents the largest
population treated in this setting reported to date. PERUSE
includes patients representative of routine oncology practice,
such as those who may not be suitable for docetaxel therapy and a
substantial proportion (45% of patients initially diagnosed with
early breast cancer) previously treated with trastuzumab (29% of
the overall population compared with 12% in CLEOPATRA [1]).
Preliminary findings suggest that the safety and efficacy of first-
line pertuzumab combined with trastuzumab and standard
taxane therapy for HER2-positive LR/MBC are consistent with
results from the phase III CLEOPATRA trial [1, 2]. Preliminary
PFS results suggest activity for all three combinations in line with
the 18.5-month median PFS observed in CLEOPATRA with per-
tuzumab, trastuzumab and docetaxel [1]. In PERUSE, median
PFS was 20.6 months overall and 19.6, 23.0 and 18.1 months
in the docetaxel, paclitaxel and nab-paclitaxel subgroups, respect-
ively. ORRs were also similar in the two trials (80% in both
CLEOPATRA and overall in PERUSE; 79%, 83% and 77% in the
docetaxel, paclitaxel and nab-paclitaxel subgroups, respectively,
of PERUSE), although we acknowledge the limitations of cross-
trial comparisons.
The safety profile of pertuzumab, trastuzumab and taxane
regimens in PERUSE was also generally consistent with results
from CLEOPATRA, characterised by all-grade diarrhoea, alope-
cia, nausea and fatigue and grade 3 diarrhoea and haemato-
logical toxicities. However, there was a notably lower incidence
of neutropenia and febrile neutropenia in PERUSE compared
with CLEOPATRA. This may be partly explained by the chemo-
therapy backbone, as incidences of febrile neutropenia were less
Figure 1. Most common (>2% of patients in any subgroup) grade 3 adverse events by initially selected taxane. ALT, alanine aminotransfer-
ase; AST, aspartate aminotransferase.
Table 2. Best overall response in patients with measurable disease at baseline
Response, N (%) All patients (N5 1199) Docetaxel (N5 657) Paclitaxel (N5483) Nab-paclitaxel (N5 53)
ORR [95% Clopper–Pearson CI] 959 (80) [78–82] 517 (79) [75–82] 400 (83) [79–86] 41 (77) [64–88]
Complete response 175 (15) 89 (14) 83 (17) 3 (6)
Partial response 784 (65) 428 (65) 317 (66) 38 (72)
Stable disease 180 (15) 108 (16) 62 (13) 9 (17)
Progressive disease 50 (4) 25 (4) 19 (4) 3 (6)
Not evaluable 10 (1) 7 (1) 2 (<1) 0
Patients with complete or partial response were considered as responders. Patients without a post-baseline tumour assessment were considered as
non-responders. Patients with no post-baseline tumour assessment who discontinued treatment because of clinical progression were considered to have
progressive disease as best overall response (N¼ 2).
CI, confidence interval; ORR, overall response rate.
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different between CLEOPATRA (14%) and the docetaxel sub-
group of PERUSE (11%). Furthermore, weekly taxane schedules
may be associated with less neutropenia than q3w schedules
[12, 13].
Focusing on differences between taxane subgroups within
the PERUSE study, neuropathy was observed most frequently
in the paclitaxel subgroup. However, febrile neutropenia was
less common with paclitaxel-containing than docetaxel-
containing regimens. These results are consistent with clinical
experience of each chemotherapy. This more manageable safety
profile, combined with the similar or better efficacy of weekly
paclitaxel [13], contributes to many clinicians’ preference for
paclitaxel combination regimens instead of the approved doce-
taxel regimen.
PERUSE findings complement results from the CLEOPATRA
trial, indicating that findings from a phase III trial can be replicated
in the routine clinical practice setting. The results also expand
upon recently published retrospective and real-world studies of
patients treated with pertuzumab, trastuzumab and the investiga-
tor’s chosen taxane in the United States, Italy and Turkey, which
reported median PFS ranging from 17 to 29 months [14–17].
Strengths of PERUSE results compared with previous reports
include the prospective nature of the study, the larger proportion
of patients treated with paclitaxel instead of docetaxel, the more
rigorous data collection and the regular schedule of tumour assess-
ment according to RECIST (version 1.1).
A limitation of PERUSE is the single-arm open-label design
lacking a control arm. Limitations of the preliminary analyses
reported here include the exploratory nature of these subgroup
analyses, which may be biased by differences in patient selection,
regional oncology practice and confounding factors at baseline,
the relatively few patients treated with nab-paclitaxel and the cur-
rent absence of OS results. Nevertheless, ORR, PFS and more fa-
vourable tolerability with paclitaxel, despite the slightly older
age, worse performance status and higher proportion of
patients with recurrent metastatic disease, provide reassurance
that paclitaxel (or nab-paclitaxel) is a reasonable alternative
in patients for whom docetaxel may not be considered optimal
or appropriate.
In conclusion, these results from the PERUSE study after
a median follow-up of >4 years support the use of paclitaxel or
nab-paclitaxel as alternatives to docetaxel in combination with
first-line pertuzumab and trastuzumab for HER2-positive LR/
MBC. Efficacy in the paclitaxel and nab-paclitaxel subgroups
appeared similar to that observed with docetaxel; the more fa-
vourable safety profile suggests that paclitaxel or nab-paclitaxel
may be valid alternatives to docetaxel with pertuzumab and
trastuzumab. Final results from the PERUSE study are expected
in 2020.
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